ArticleCureus2026
Multiple Sclerosis With Migraine and Pyoderma Gangrenosum Treated With Ofatumumab and Erenumab.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. Migraine is a common comorbidity in MS, with primary headache syndromes frequently observed. Ofatumumab, a high-efficacy anti-cluster of differentiation 20 (CD20) monoclonal antibody, and erenumab, a calcitonin gene-related peptide (CGRP) receptor antagonist, are available as subcutaneously administered monoclonal antibody agents. Despite their independent efficacy, there is limited evidence regarding the concurrent use of these two agents in patients with MS and migraine, especially in those with dermatological conditions such as pyoderma gangrenosum. We treated a 43-year-old Japanese woman with relapsing-remitting MS (RRMS), migraine, and pyoderma gangrenosum. She experienced persistent migraines despite valproic acid and sumatriptan use. After the administration of intravenous methylprednisolone (IVMP), ofatumumab treatment was introduced; erenumab was later initiated to manage migraines. The addition of erenumab reduced the patient's monthly migraine days (MMDs) and monthly headache days (MHDs). No progression of MS or worsening of pyoderma gangrenosum was observed. The Expanded Disability Status Scale (EDSS) score remained stable, and cognitive function was preserved. The combination therapy demonstrated effectiveness without exacerbating the patient's underlying dermatological condition. This case suggests that combining ofatumumab and erenumab is a viable therapeutic option for patients with MS and comorbid migraine and pyoderma gangrenosum, offering effective disease control with an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.